Effectiveness of Oropharyngeal Suctioning in Preventing Ventilator-Associated Pneumonia: A Random… (NCT07128537) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Effectiveness of Oropharyngeal Suctioning in Preventing Ventilator-Associated Pneumonia: A Randomized Controlled Trial.
100 participantsStarted 2025-09-10
Plain-language summary
Ventilator-Associated Pneumonia (VAP) is a serious infection that affects patients who are on mechanical ventilation in intensive care units (ICUs). It can increase the risk of death, prolong hospital stays, and lead to higher healthcare costs. This study is designed to evaluate the effectiveness of scheduled oropharyngeal suctioning (removal of secretions from the mouth and throat) every 4 hours in preventing early-onset VAP in ICU patients who require mechanical ventilation for more than 48 hours.
The study will compare two groups of ICU patients: one group will receive scheduled oropharyngeal suctioning every 4 hours in addition to standard oral care, while the other group will receive only standard oral care. The main goal of the study is to determine whether regular suctioning reduces the incidence of VAP, improves patient recovery, and shortens the duration of mechanical ventilation.
This research will help clarify whether adding scheduled suctioning to standard care can prevent VAP and improve clinical outcomes for critically ill patients, potentially leading to better practices in ICU care.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* ICU patients aged 18-75 years.
* Patients expected to require invasive mechanical ventilation for more than 48 hours.
* Modified Clinical Pulmonary Infection Score (MCPIS) ≤ 5 on Day 1, indicating no or minimal signs of infection.
* Ability to comply with the study protocol, including informed consent from patient attendants.
Exclusion Criteria:
* Patients with chronic respiratory diseases (e.g., COPD, asthma).
* Immunocompromised patients (e.g., those with cancer, organ transplant recipients, or on immunosuppressive therapy).
* Patients with ongoing sepsis or severe infections at the time of enrollment.
* Patients who have been on mechanical ventilation for more than 48 hours at the time of ICU admission.
* Pregnant patients or those unable to comply with the study protocol.
* Patients with dental prosthetics or dentures, as these may interfere with the suctioning process.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
incidence of early-onset Ventilator-Associated Pneumonia (VAP) in mechanically ventilated ICU patients.
Timeframe: The primary outcome measure, incidence of early-onset VAP, will be assessed from Day 1 to Day 5 of mechanical ventilation in the ICU, specifically during the period of scheduled oropharyngeal suctioning intervention.